Intec Pharma says it expects the Phase III trial for its Accordion Pill Levodopa to take place in the second half of 2015.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Intec Pharma Ltd. (TASE: INTP) reported today that it had received US Food and Drug Administration (FDA) approval for carrying out a Phase III trial of its Accordion Pill Levodopa for the treatment of Parkinson’s Disease. The Accordion Pill is a gastro-retentive drug delivery system.
Intec says that it will conduct discussions with the FDA on the protocol for the trial. The company estimates that the trial, whether carried out independently or in collaboration with a leading pharmaceuticals company, will take place in the second half of 2015.
Intec chairman Zvi Joseph said, “We are very proud and happy that the FDA has given us approval for entering into a Phase III trial for the Accordion Pill Levodopa that Intec Pharma has developed. The clinical effect obtained to date, together with the high safety profile demonstrated in all the trials, indicate the potential of Accordion Pill Levodopa to become a leading treatment for Parkinson’s.”
Israel Business Conference 2014 – Registration and details >>
Published by Globes [online], Israel business news – www.globes-online.com